Indications and Donor Selections for Allogeneic Stem Cell Transplantation in Children with Hematologic Malignancies
Allogeneic stem cell transplantation (SCT) is the only curative approach for many patients with advanced or high-risk leukemia. Advances in supportive care and management of graft-versus-host disease have resulted in improvements in outcomes of related and unrelated donor SCT, creating controversies as to which strategy might be the optimal therapy for individual patients. This article discusses the indications and donor selection strategies for SCT in patients with malignant hematologic disease.
aDepartment of Hematology/Oncology and General Pediatrics, Children's University Hospital, Hoppe-Seyler-Strasse 1, 72076 Tuebingen, Germany
bPediatric Bone Marrow and Stem Cell Transplant Program, Duke University Medical Center, Box 3350 Durham, NC 27710, USA
cDepartment of Pediatrics, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, the Netherlands